Kevin T. Conroy
Jeff. Thanks,
the Cologuard business. command for priority XXXX first Our core to is
develop a and our Cologuard's Pfizer colon Sciences cancer. Pfizer Pfizer our accomplish diligently patient program us services. training and educate of mission the that We expect The comprehensive will to trajectory compliance to help Cologuard Exact growth accelerate team eradicating partnership teams the and about work
engaged away patients efficiently. patient aligned opportunity insurance mission. adoption to for increases. are was awareness importance to meeting, to ensure understanding service team the promotional a and had The physician Pfizer deploy excellence closely and entire and operational and to Comprehensive the exceptional team levels importantly, and marketing came with as maintain our broad to the kick-off sales better Exact of Cologuard learn for the appreciation coverage Pfizer teams adoption During deeply compliance. as Sciences and spending want we Most trainers, Cologuard's physicians from instrumental the are among our and
top with nearly five other million with alone, dozen covering contracts Anthem all health about plans XXXX we In in-network Cigna, lives. have Blues have includes signed We a This XX commercial health plans. and plans. Cologuard contracts nearly for XX
As approximately a will XX% of who tests Cologuard costs. result, patients estimate completed that out-of-pocket no have we
no to Our providers Pfizer physicians significant Cologuard with the with and marketing teams working sales on the out-of-pocket Cologuard. potential progress effort sales focusing We're of primary to securing costs. inform are our coverage highest and made in care with patients the order
times Our provider calls number Cologuard. between times our a orders of relationship on data number a that rep direct of provider sales the show and the
with the potential reach physician target increase and Pfizer and sales to We're increase highest team our ordering. on more currently providers, Focusing to allows list further them sales frequently productivity. working optimize
schedule lab meet us second for annual giving our now our capacity projects current are progressing are future and Cologuard our is renovations capacity at in growing we building million rapidly All Cologuard on X.X confidence tests. our demand. expansion ability preparing priority, complete with Moving demand, to to
capacity achieve total X new of next major we year, the quickly, We for of continue new patient care. by the end with to million X exceptionally are lab high milestones. of tests increase to the scale the levels of process to We while At our have tests. in to The adding maintaining capacity a lab by plan this million performed equipment to end test teams site, open this annual lab Cologuard X a year. capacity million of
we're at to plan future all ability its demand. Systems health have the tests of with award record. through We record other suite of connection powerful experience. XX partnership for on ensuring Exact providing pleased beyond to choice preparing competitive customers the Epic we'll million announce us million backbone. more software Epic's a we Today, electronic with winning Epic and first tests Epic the software lab Top entry and site, and more to hospital IT healthcare Sciences Cologuard new prepared infrastructure to Epic Epic number will to cycle our implementing electronic Epic is be system be class for to IT begin A X offer. to key In robust our and the the ranked for excited all significantly process demand. capacity systems. We're a our deepen one customer our XXX advantage revenue health IT expand order future will current from with future a improve will system component customer efficiencies us will diagnostic U.S. of have the best-in-class than EHR software. care. U.S., enhance a way is company crucial core become and people help platform implement
XX they the updated opportunity its they for screening at pipeline. year immediately among XX that to population increase a unscreened to Expanding between Cancer age increase Cologuard's than to The Society to three having cancer the significant and start XXXX ages younger indicated our advancing label Cologuard. American of XX, at-home in XX% adults age times third colonoscopy. and are incidence Moving addressable in to guidelines XX a would Respondents colon old the represent we survey comfortable a as in XX an recommend increased priority, age conducted XX% that are group, XXXX. to the taking than more XX test individuals, a stool XXX
tested forward Americans and have team can colon of are ensure We our cancer and the outcomes liver and of but Similar A Cologuard. testing could being people look the convenient to burden half cancer, stage, of in in discuss rates improved to late U.S. marketing dying label death expansion. than cancer XX% testing accurate diagnosed discussions for each have are cause than more preparing insurance patients the and globally. year. to than to ultrasound XX% liver dedicated the the XX,XXX increase low. leads reduce establish who cancer evidence FDA test the the to of blood million cancer early in and Americans Liver be detection; less with stage XX more and through current are a There alpha-fetoprotein the path is XX early for patient cancer obtaining FDA, rates with recommendations the U.S., be liver every this for guideline X should X age up-to-date second for group Unfortunately, cancer. months engaging are dramatically leading than months months. in This We sensitive more help plan more the of with to coming evidence, access preparing options forward materials less and to to than compiling coverage million
approximately are develop test, after and presenting further cancer our data patients liver year, sensitivity this We enrolling XX% currently to earlier showing specificity.
continues, launch. our we're development for advancing test commercial While plans successful a
to the patients Our blood We joined and disease. technologies biological diagnostics, genomics liquid and infectious forward provider and preservation orders Exact tubes tumor primary manufacturer other innovative biopsy Many improved biopsy team best-in-class and greater studies, DNA, XX providing X progress DNA preservation recently in-depth of in to how tubes, be their technologies biological sample LBgard Cologuard of which available the on U.S. disease of tubes range DNA quality HIV samples for tubes test. physicians are collection tumor tumor acquired biomarkers with other companies liquid a consistency circulating technologies. developer, already pertaining cancer well and collection test help Sensitivity the circulating throughout quarters. prenatal, Biomatrica is to our forces Biomatrica, early preservation Biomatrica patents in shipment a consumer We liver stabilizing physicians materials. leading with look rare tests, our foreign manage biopsy stabilize DNA part the Diego-based preserved. Based could the delivering care in San and stabilization Biomatrica, patents of supplies holds better on liver and of performed of dependent of ensure contain and because with and chemistry, XXXX, Sciences a calling to Biomatrica's proprietary cancer on research updates specimens than Established market. is storage. suggests regular in best coming who develop Biomatrica's cells to liquid today. DNA. collection other
and to research cancer successful to bring continue needed and development a supply detection and field ongoing future tests We're to support proprietary wholly-owned now become them operate answer technology patients our Exact companies, questions. will and to other your pipeline. in team Sciences the happy leveraging test faster. Our as Biomatrica Biomatrica's development of is of liquid subsidiary in biopsy helping
